Daniel E. Fürst
Impact in
- Rheumatology top 0.01%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Hematology top 0.2%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Rheumatology 135
- Rheumatoid Arthritis Research and Therapies 122
- Systemic Lupus Erythematosus Research 35
-
- Systemic Sclerosis and Related Diseases 67
- Co-authors
- Michael H. Weisman (11 shared papers)Ravinder N. Maini (6 shared papers)Peter E. Lipsky (6 shared papers)Paul Emery (7 shared papers)E. William St. Clair (4 shared papers)Joachim R. Kalden (3 shared papers)Gregory R. Harriman (2 shared papers)Marc Feldmann (2 shared papers)
- Journals
- Annals of the Rheumatic Diseases (36 papers)Lara D. Veeken (16 papers)The Journal of Rheumatology (15 papers)Seminars in Arthritis and Rheumatism (11 papers)Arthritis Care & Research (8 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Daniel E. Fürst
261 papers receiving 21.9k citations
Daniel E. Fürst's Hit Papers
Peers
Comparison fields: 5 of 172
- Rheumatology 11.3k
- Hematology 3.1k
- Pathology and Forensic Medicine 4.0k
- Immunology 3.5k
- Genetics 1.4k
Countries citing papers authored by Daniel E. Fürst
This map shows the geographic impact of Daniel E. Fürst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Fürst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Fürst more than expected).
Fields of papers citing papers by Daniel E. Fürst
This network shows the impact of papers produced by Daniel E. Fürst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Fürst. The network helps show where Daniel E. Fürst may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel E. Fürst, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 265 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis Hit paper breakdown → | 2000 | 2540 |
| 2 | American college of rheumatology preliminary definition of improvement in rheumatoid arthritis Hit paper breakdown → | 1995 | 2272 |
| 3 | Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Hit paper breakdown → | 1999 | 1950 |
| 4 | The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials Hit paper breakdown → | 1993 | 1351 |
| 5 | American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis Hit paper breakdown → | 2010 | 553 |
| 6 | Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Hit paper breakdown → | 2005 | 519 |
| 7 | Methotrexate for Rheumatoid Arthritis Hit paper breakdown → | 1994 | 479 |
| 8 | Microchimerism and HLA-compatible relationships of pregnancy in scleroderma Hit paper breakdown → | 1998 | 473 |
| 9 | 2004 | 446 | |
| 10 | 1994 | 430 | |
| 11 | 1999 | 384 | |
| 12 | 2005 | 365 | |
| 13 | 2006 | 351 | |
| 14 | 2011 | 329 | |
| 15 | Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients Hit paper breakdown → | 2012 | 298 |
| 16 | 2007 | 268 | |
| 17 | 2012 | 245 | |
| 18 | 1999 | 235 | |
| 19 | The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. | 1998 | 231 |
| 20 | 2001 | 230 |
About Daniel E. Fürst
Daniel E. Fürst is a scholar working on Rheumatology, Pathology and Forensic Medicine, Immunology, Genetics and Hematology, having authored 265 papers that have together received 23.3k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (122 papers), Systemic Sclerosis and Related Diseases (67 papers), Systemic Lupus Erythematosus Research (35 papers), Chronic Lymphocytic Leukemia Research (20 papers), Autoimmune and Inflammatory Disorders Research (16 papers), Biosimilars and Bioanalytical Methods (15 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (15 papers) and Inflammatory Myopathies and Dermatomyositis (13 papers). The work is most often cited by research in Rheumatology (11.3k citations), Hematology (3.1k citations), Pathology and Forensic Medicine (4.0k citations), Immunology (3.5k citations) and Genetics (1.4k citations). Daniel E. Fürst has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Michael H. Weisman, Ravinder N. Maini, Peter E. Lipsky, Paul Emery, E. William St. Clair, Joachim R. Kalden, Gregory R. Harriman, Marc Feldmann, Ferdinand C. Breedveld and Josef S Smolen. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, The Journal of Rheumatology, Seminars in Arthritis and Rheumatism and Arthritis Care & Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.